Orflo Technologies is an innovative life sciences company with a portfolio of powerful yet simple cell analysis instruments and associated consumables for the cell and gene therapy markets.
Through this acquisition, Gemini Bio will strengthen their ability to deliver high-quality solutions to cell culture laboratories around the world. Through this acquisition, Orflo will gain access to Gemini’s dedicated commercial organization enabling reach to more customers, accelerating the pace of cell culture insights and transformational therapy development.
ORFLO’s innovative technology fits naturally into Gemini’s portfolio of solutions for cell and gene therapy research.
Read the press release here: Sikich Investment Banking Advises ORFLO Technologies in Acquisition by Gemini Bio